Mapping an emerging framework for regenerative medicine reimbursement

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

Go to the profile of Regenerative Medicine
Dec 11, 2017
0
0
Like 0 Comment

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled 'The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics' from Aurélie Mahalatchimy & Alex Faulkner [1].

The development of regenerative medicines (RMs) carry substantial risks for companies because production costs are often large and products are yet to show effective long-term results. A broad examination of published literature in the field of RM shows there is a growing discussion about policies that aim to encourage the development of RMs through risk-sharing policies. Interviews with numerous organisations in the field of RM showed that trade associations are the most active in considering ways to structure financial reimbursement for the RM industry.

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here:
https://www.eurostemcell.org/regenerative-medicine-society/mapping-emerging-framework-regenerative-medicine-reimbursement

The full original article can be accessed here:
https://www.futuremedicine.com/doi/10.2217/rme-2017-0041


References

[1] Mahalatchimy A, Faulkner A. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics. Regen. Med. 12(6), 611–622 (2017).

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.